Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy

Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy

BackgroundEsophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer in China. The use of neoadjuvant immunotherapy for the treatment of ESCC is gradually increasing. Camrelizumab is one such immune checkpoint inhibitor (ICI) used for treatment. In this retrospective stud...

Full description

Bibliographic Details
Main Authors: Yujin Qiao, Cong Zhao, Xiangnan Li, Jia Zhao, Qi Huang, Zheng Ding, Yan Zhang, Jia Jiao, Guoqing Zhang, Song Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Immunology
Subjects:
esophageal squamous cell carcinoma (ESCC)
camrelizumab
immune checkpoint inhibitor (ICI)
neoadjuvant chemotherapy
efficacy
surgery
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.953229/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.953229/full

Similar Items